Facebook Users

Will SDIX go up?

SDIX Strategic Diagnostics Inc. featured news, full reports, and detailed charts

Strategic Diagnostics Inc. (SDIX) Wrap Up:

Strategic Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and markets antibody products and analytical test kits for a range of food, water, agricultural, industrial, environmental, and scientific applications in the United States and internationally. The company primarily focuses on immunology, proteomics, bio-luminescence, and other bio-reactive technologies. It offers a range of monoclonal and polyclonal antibody products and services in the areas of hybridoma development, cell culture techniques, large-scale ascites and antisera production, large-scale antibody purification, chemical modification of immunogens and antibodies, and characterization of antibodies ...
www.sdix.com
166 Employees
Founded in 1987

Strategic Diagnostics Inc. (SDIX:NASDAQ)

LAST $1.35 USD
CHANGE TODAY -0.0488 -3.49%
VOLUME 11.2K
As of 3:59 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).

Snapshot of Strategic Diagnostics Inc. (SDIX)

OPEN
$1.39
PREVIOUS CLOSE
$1.40
DAY HIGH
$1.40
DAY LOW
$1.35
52 WEEK HIGH
08/21/09 - $2.25
52 WEEK LOW
12/24/08 - $0.71
MARKET CAP
27.5M
AVERAGE VOLUME 3 mo
21.6K
DILUTED EPS TTM
$-0.69
SHARES OUTSTANDING
20.4M
SDIX Does Not Pay Dividends
P/E TTM
NM
K = Thousands  M = Millions  B = Billions

SDIX Top Compensated Officers

Mr. Francis M. DiNuzzo
Chief Executive Officer, President and Direct...
Age: 53
Total Annual Compensation: $243.0K
Dr. James W. Stave Ph.D.
Chief Science Officer and Vice President of R...
Age: 54
Total Annual Compensation: $236.2K
Mr. Matthew Knight
Consultant
Age: 52
Total Annual Compensation: $338.0K

Executives, Board Directors

Compensation as of Fiscal Year 2008.

Key developments for Strategic Diagnostics Inc. (SDIX)

Strategic Diagnostics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009

Strategic Diagnostics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported revenues were $7.2 million compared to $6.9 million for the same period in 2008. Revenues for the third quarter of 2009 were positively impacted by a 29% increase in revenues from Life Science products compared to the third quarter of 2008. Operating loss for the third quarter fell to $281,000, compared to $1.1 million in the third quarter of 2008. Pre-tax loss for the third quarter of 2009 was $290,000 compared to $1.1 million for the prior year's third quarter. Net loss for the third quarter of 2009 was $291,000 or $0.01 per diluted share, compared to a net loss of $2.2 million or $0.11 per diluted share, for the third quarter last year. For the nine months ended September 30, 2009, the company reported revenues were $21 million compared to $20.6 million for the same period last year. The company reported operating loss of $281,000, pre-tax loss of $290,000 and net loss of $291,000 or $0.08 per diluted share compared to operating loss of $1,134,000, pre-tax loss of $1,099,000 and net loss of $2,218,000 or $0.16 per diluted share for the same period a year ago.

Strategic Diagnostics Inc., Q3 2009 Earnings Call, Oct-29-2009

Strategic Diagnostics Inc., Q3 2009 Earnings Call, Oct 29 2009

Strategic Diagnostics Inc. and DuPont Qualicon Enter into an Amended and Restated Distribution Agreement

On August 31, 2009, Strategic Diagnostics Inc. and the DuPont Qualicon entered into an amended and restated distribution agreement, effective as of such date. Under the amended and restated distribution agreement, the parties expanded their existing arrangement to include proprietary RapidChek® SELECT-TM-products, which had previously not been covered by the arrangement, along with RapidChek E. coli O157:H7, Salmonella and Listeria products. DuPont Qualicon markets these products outside the United States as the DuPont-TM-Lateral Flow System. The term of the Agreement commenced as of August 31, 2009 and continues through December 31, 2011 and thereafter for successive one year periods unless or DuPont Qualicon provides the other party notice of its intent not to renew at least 90 days prior to the end of the initial term or any renewal term or unless the Agreement is otherwise terminated in accordance with its terms.

otc, otcbb, pinksheet, SDIX, ob Strategic Diagnostics Inc.

SDIX Competitors

Company Last Change
Covance Inc $52.89 USD +0.40
Elbit Vision Systems Ltd $0.08 USD -0.008
Meridian Bioscience Inc $20.85 USD -0.30
Neogen Corp $33.21 USD +0.08
Valpey Fisher Corp $1.50 USD 0.00
Market data is delayed at least 20 minutes.

Industry Analysis

Valuation SDIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x

SDIX

 | 

SDIX transactions

Type
Date
Target
No transactions in the last 6 months.

More Recent News About Strategic Diagnostics Inc.

More news for SDIX

Strategic Diagnostics Inc. and DuPont Qualicon Expand Global Distribution Agreement

NEWARK, Del. & WILMINGTON, Del.--(BUSINESS WIRE)--SDI (Strategic Diagnostics Inc., NASDAQ:SDIX), a leading provider of biotechnology-based detection solutions for food safety and life science applications, and Wilmington, DE-based, DuPont Qualicon today announced the expansion of their distribution agreement to include SDI’s proprietary RapidChek® SELECT™ products. E. coliSalmonellaListeria outside the United States as the DuPont™ Lateral Flow System. Under the terms of the expanded agreement, DuPont Qualicon will now also market SDI’s RapidChek® SELECT™ tests and proprietary enrichment media under the same name. SDI will continue to market its RapidChek and RapidChek SELECT line of food pathogen test systems directly in the United States and through selected distributors outside the U.S.RapidChek and RapidChek SELECT are easy to use, accurate and affordable pathogen detection systems. Each test focuses on the total process, optimizing both the enrichment and the detection portion of the test system. All systems have a proprietary enrichment broth, ensuring superior recovery and growth of the target pathogen, if present in the food sample. In addition, the test strips provide clear and rapid results.Tim Lawruk, SDI Food Safety Marketing Manager said, “Given the globalization of the food market, the global customer base needs to have consistent quality systems and testing methodologies around the world. We believe this will drive them to employ fast, accurate, and cost-effective technologies such as RapidChek. Expanding our relationship with DuPont Qualicon to include our proprietary SELECT platform will allow both DuPont Qualicon an...
Click here to read the whole Article (external link)

STRATEGIC DIAGNOSTICS INC/DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement

Show all filings for STRATEGIC DIAGNOSTICS INC/DE/ | Request a Trial to NEW EDGAR Online Pro Form 8-K for STRATEGIC DIAGNOSTICS INC/DE/ 4-Sep-2009Entry into a Material Definitive Agreement Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for infor...
Click here to read the whole Article (external link)

SDI Offers Free Webinars to Help Life Scientists Get Better Antibodies in Less Time

NEWARK, Del.--(BUSINESS WIRE)--SDI (Strategic Diagnostics Inc., NASDAQ: SDIX) will host three free online lectures during October and November this year to help scientists enhance their research process flow using a new technology. For over 20 years, SDI has created antibodies that advance immuno-based work helping scientists and other customers reduce time, labor, and costs while increasing accuracy and reliability of test results. WHAT:SDI will host three free online lectures to help research scientists learn how antibodies can be generated directly from a protein sequence using Genomic Antibody Technology (GAT).WHO:The webinars are intended for researchers from pharmaceutical, academic, diagnostic, government and other life science organizations. The online lectures will be presented by Dr. Ross Chambers, Senior Scientist at SDI. Dr. Chambers is an expert on the development of antibodies based on DNA immunization technologies. Prior to joining SDI, Dr. Chambers was an Assistant Professor at the University of Texas Southwestern Medical Center.WHERE:Online, at your computer location. To register, go to www.sdix.com/attend or call us at 800-544-8881.WHEN:WHY: Seminar attendees will learn how they can benefit from of GAT, including:About Strategic Diagnostics Inc. (SDI)Strategic Diagnostics Inc...
Click here to read the whole Article (external link)

Strategic Diagnostics to Report Third Quarter Results on October 29, 2009

NEWARK, Del.--(BUSINESS WIRE)--Strategic Diagnostics Inc. (Nasdaq:SDIX - News) - a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, expects to release its third quarter 2009 results at approximately 4 p.m. ET on Thursday, October 29, 2009. The Company has scheduled an investor conference call for 4:30 p.m. ET on the same day. The dial-in number for the live conference call will be 877-407-9210 (201-689-8049 outside the U.S.). A live webcast of the conference call will be available on the Company’s website, www.sdix.com, as well as www.vcall.com. For those who cannot listen to the live broadcast, an audio replay of the call w...
Click here to read the whole Article (external link)

Q3 2009 Strategic Diagnostics Earnings Release - 4:00 pm ET

Earnings Announcements for Thursday, October 29CompanySymbolTimeConferenceCall3PAR Inc.PARAfter Market CloseListenABBABB01:00 am ETABG SUN COL HLDGASC.OLTime Not SuppliedAccuray IncorporatedARAYAfter Market CloseListenACHENG RELAY000922.SZTime Not SuppliedAcme Packet, Inc.APKTAfter Market CloseListenAcme UnitedACU09:00 am ETListenACS, Actividades de Construcción y Servicios, S.A.ACS.MCAfter Market CloseACTELIOSACT.MI10:00 am ETActuate CorporationACTUAfter Market CloseListenAdaptec, Inc.ADPTTime Not SuppliedListenAdolor CorporationADLRTime Not SuppliedListenADVA Optical NetworkingADV.FTime Not SuppliedListenAetna Inc.AETBefore Market OpenListenAGL ResourcesAGLBefore Market OpenListenAgree Realty...
Click here to read the whole Article (external link)

Strategic Diagnostics Reports Third Quarter 2009 Results

  STRATEGIC DIAGNOSTICS INC. AND SUBSIDIARIES       CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (unaudited)   Three Months Nine Months   Ended September 30, Ended September 30,   2009   2008 2009   2008   Revenues $ 7,196   $ 6,892   $ 20,951   $ 20,631   ...
Click here to read the whole Article (external link)

SmallCapSentinel.com: Records and Revenues

LAS VEGAS, Nov. 3, 2009 (GLOBE NEWSWIRE) -- According to news this morning by Metiscan, Inc. (Pink Sheets:MTIZ - News), a holding company focused on growing its organization by making key acquisitions and developing companies and emerging technologies, patients could soon be given the opportunity to review their personal diagnostic imaging reports online. Metiscan's wholly owned subsidiary, FirstView EHR, has entered into a partnership with The Estate Vault to use its comprehensive electronic online repository for consolidating and protecting medical, personal, financial, and legal records. Via the partnership, the two firms will collectively create a HIPPA compliant electronic interface, linking synergistic systems together such that patients will have direct access to their imaging reports. Metiscan anticipates that the partnership will provide the company with the opportunity to potentially generate in excess of one half million dollars in new revenues over the next 3 years. Additionally, it will offer FirstView the ability to position its service to include delivery of the patient record directly to the patient as part of its workflow. A profile featuring diagnostic imaging company Metiscan, Inc. (Pink Sheets:MTIZ - ...
Click here to read the whole Article (external link)

STRATEGIC DIAGNOSTICS INC/DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements

Show all filings for STRATEGIC DIAGNOSTICS INC/DE/ | Request a Trial to NEW EDGAR Online Pro Form 8-K for STRATEGIC DIAGNOSTICS INC/DE/ 29-Oct-2009Results of Operations and Financial Condition, Financial Statements Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All informat...
Click here to read the whole Article (external link)

STRATEGIC DIAGNOSTICS INC/DE/ Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Forward-Looking Statements This Form 10-Q contains certain forward-looking statements reflecting the current expectations of Strategic Diagnostics Inc. and its subsidiaries (the "Company" or "SDI"). In addition, when used in this quarterly report, the words "anticipate," "enable," "estimate," "intend," "expect," "believe," "potential," "may," "will," "should," "project" and similar expressions as they relate to the Company are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers, attraction and retention of management and key employees, adequate supply of raw materials, inability to obtain or delays in obtaining third party approvals or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, the ability to obtain financing and other factors more fully described in the Company's public filings with the SEC including, without limitation, the Company's Annual Report on Form 10-K for the year ended December 31, 2008. Background SDI is a biotechnology company with a core mission of developing, commercializing and marketing innovative and proprietary products, services and solutions that preserve and enhance the quality of human health and wellness. The Company believes that its competitive position has been enhanced through the combination of talen...
Click here to read the whole Article (external link)

Would you like to leave a comment about Strategic Diagnostics Inc. SDIX

Besides Strategic Diagnostics Inc. there is more great information available at Realpennies.com